New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
06:34 EDTOGXIOncoGenex initiates Cedar clinical trial evaluating apatorsen
OncoGenex Pharmaceuticals announced initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating apatorsen in previously untreated patients with advanced squamous cell lung cancer. Apatorsen is a once-weekly intravenous experimental drug that is designed to inhibit production of heat shock protein 27 to disable cancer cells' defenses and overcome treatment resistance.
News For OGXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 30, 2015
08:43 EDTOGXIOncoGenex enters share purchase agreement with Lincoln Park Capital
Subscribe for More Information
07:30 EDTOGXIOncoGenex amends custirsen Phase 3 trial for lung cancer
OncoGenex has filed an amendment with the FDA, as well as initiated filing with regulatory agencies in other countries, to amend the statistical design and analysis plan of its pivotal, international Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of non-small cell lung cancer. OncoGenex recently regained the rights to the investigational compound from Teva Pharmaceuticals and is currently in the process of assuming sponsorship for all clinical development related to custirsen. The protocol amendment is designed to reduce the number of required patients enrolled in the trial and include an earlier, more rigorous second interim futility analysis. These changes do not affect the criteria for enrollment or conduct of the study, which continues to accrue patients. Enrollment is expected to be completed in 2H16.
April 27, 2015
06:34 EDTOGXIOncoGenex subsidiary executes termination agreement with Teva
Subscribe for More Information
06:33 EDTOGXIOncoGenex regains rights to custirsen executes termination agreement with Teva
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use